Volver a Agenda
Session Chair(s)
Lina AlJuburi, PHARMD, MSC
Head, Regulatory Science and Policy, North America
Sanofi, United States
Learning Objective : Discuss trademark development and review processes; Identify the important role of trademarks; Assess take-away points to improve internal company processes.
Speaker(s)
FDA Perspective
Kellie Taylor
FDA, United States
Associate Director, OMEPRM, OSE, CDER, FDA
Health Canada's Revised Guidance For Industry: Review of Brand Names Past, Present, and Future
Cathy A. Parker
Health Canada, Canada
Director General, Biologics & Genetic Therapies Directorate HPFB
EMA Perspective
Isabelle Moulon, MD
European Medicines Agency, Netherlands
Head of Patients and Healthcare Professionals Department
¿Tiene una cuenta?